|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.
100 Clinical Results associated with Indalo Therapeutics, Inc.
0 Patents (Medical) associated with Indalo Therapeutics, Inc.
100 Deals associated with Indalo Therapeutics, Inc.
100 Translational Medicine associated with Indalo Therapeutics, Inc.